$GRPH News
Last published 2y ago
- 2y agoGRPHGraphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz TherapeuticsBusiness WireSpecial dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of
- 2y agoEVRIFIXXGRPHSCTLKuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law FirmGlobeNewswireNEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoDSKEGRPHROVRRYZBKuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoGRPHLENZ Therapeutics and Graphite Bio Announce Merger AgreementBusiness Wire- Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately
- 3y agoGRPHPEAKHealthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common StockBusiness WireHealthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD
- 3y agoGRPHGraphite Bio Announces Departure of Chief Financial OfficerBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH) today announced that Alethia Young, the Company's Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through
- 3y agoGRPHGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial ResultsBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. "As announced last month, Graphite Bio has initiated a process to evaluate strategic
- 3y agoGRPHGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate RestructuringBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further
- 3y agoGRPHGraphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell DiseaseBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first
- 3y agoGRPHGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual MeetingBusiness WireSingle-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) Graphite Bio, Inc. (NASDAQ:GRPH), a
- 3y agoGRPHGraphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx ConferenceBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious
- 4y agoGRPHGraphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial ResultsBusiness WireDosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December Entered strategic partnership with
- 4y agoGRPHGraphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and ExpositionBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious
- 4y agoGRPHGraphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National ConventionBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious
- 4y agoGRPHGraphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that members of the
- 4y agoGRPHGraphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial ResultsBusiness WireDosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; initial proof-of-concept data now anticipated in mid-2023 Presented preclinical gene repl
- 4y agoGRPHGraphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell DiseaseBusiness WireGPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Initial proof-of-concept data from Phase 1/2 CEDAR trial anticipated in mid-2023 Graphite Bio, Inc. (NASDA
- 4y agoGRPHGraphite Bio Announces Participation in Jefferies Healthcare ConferenceBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that member
- 4y agoGRPHGraphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual MeetingBusiness WireTrial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency
- 4y agoGRPHGraphite Bio Reports Recent Business Progress and First Quarter 2022 Financial ResultsBusiness WireGPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical trial on track for second half of 2022, with initial proof-of-concept data anticipated in 2023 Oral presentation highlighting
- 4y agoGRPHGraphite Bio Announces Participation in Upcoming Investor ConferencesBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that member
- 4y agoATAIBORRGRPHKALA+1Thinking about buying stock in Graphite Bio, Kala Pharmaceuticals, ATAI Life Sciences, Talos Energy, or Borr Drilling?PR NewswireNEW YORK, May 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRPH, KALA, ATAI, TALO, and BORR. To
- 4y agoGRPHGraphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell DiseaseBusiness WireGPH101 is an investigational next-generation gene-edited therapy designed to potentially provide a one-time cure for patients Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-effici
- 4y agoGRPHGraphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia ProgramBusiness WireAccepted abstracts highlight next-generation gene editing programs GPH101 for sickle cell disease and GPH102 for beta-thalassemia Chief Scientific Officer Dr. Jane Grogan to participate in scientific symposium Graphite Bio, Inc. (NASDAQ:GRPH), a c
- 4y agoGRPHGraphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual ConferenceBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., M.Phil., chief exe
- 4y agoGRPHGraphite Bio Announces Formation of Scientific Advisory BoardBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, today announced the formation of its Scientific Advisory B
- 4y agoGRPHGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial ResultsBusiness WirePatient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for second half of 2022, with initial proof-of-concept data anticipated in 2023 Prioritized R&D to m
- 4y agoGRPHGraphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care ConferenceBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that Josh Lehrer, M.D., chief executive officer of Gr
- 4y agoGRPHGraphite Bio Appoints Alethia Young as Chief Financial OfficerBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial o
- 4y agoGRPHGraphite Bio Announces Participation in Upcoming Investor ConferencesBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced participation in the following upcoming investor conf
- 4y agoGRPHGraphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and ExpositionBusiness WireTrial-in-progress poster presentation provides overview of first-in-human Phase 1/2 clinical trial in participants with severe sickle cell disease designed to evaluate safety, efficacy and pharmacodynamics of GPH101 Initial proof-of-concept data from
- 4y agoGRPHGraphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell DiseaseBusiness WireVirtual event on Tuesday, December 14, 2021, at 3 p.m. ET to discuss how the company's differentiated gene correction approach using GPH101 could lead to curative outcomes Webinar to include an encore of the company's poster presentation of the Phase
- 4y agoGRPHGraphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell DiseaseBusiness WireGPH101 designed to directly correct the genetic mutation responsible for sickle cell disease First patient expected to be treated in first half of 2022, with initial proof-of-concept data anticipated by end of 2022 Graphite Bio, Inc. (NASDAQ:GRPH)
- 5y agoGRPHGraphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial ResultsBusiness WireRecruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites Details about CEDAR trial to be presented at 63rd ASH Annual Meeting and Exposition in December $395.0 million in cash, cash equivalents an
- 5y agoGRPHGraphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and ExpositionBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that information about the company's Phase 1/2 CEDAR
- 5y agoGRPHGraphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing SummitBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that members of the management team will participate
- 5y agoGRPHGraphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National ConventionBusiness WireData support ability of company's gene editing platform to precisely and efficiently correct the underlying disease-causing mutation and restore adult hemoglobin expression with curative potential Data show minimal off-target editing using company's
- 5y agoGRPHGraphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National ConventionBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced an abstract related to the company's sickle cell dise
- 5y agoGRPHGraphite Bio Announces Participation in Upcoming September Investor ConferencesBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that members of the management team will participate
- 5y agoGRPHGraphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial ResultsBusiness WireOn track to enroll first patient in Phase 1/2 clinical trial of GPH101 for sickle cell disease in the second half of 2021 Expanded leadership team with hiring of CSO and three new appointments to board of directors Completed upsized initial public
- 5y agoGRPHGraphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireGraphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial publi
- 5y agoGRPHGraphite Bio Announces Pricing of Upsized Initial Public OfferingBusiness WireGraphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of 14,000,000 sh